176 related articles for article (PubMed ID: 33300112)
1. GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy.
Plum PS; Löser H; Zander T; Essakly A; Bruns CJ; Hillmer AM; Alakus H; Schröder W; Büttner R; Gebauer F; Quaas A
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1031-1040. PubMed ID: 33300112
[TBL] [Abstract][Full Text] [Related]
2. Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma.
Lin L; Bass AJ; Lockwood WW; Wang Z; Silvers AL; Thomas DG; Chang AC; Lin J; Orringer MB; Li W; Glover TW; Giordano TJ; Lam WL; Meyerson M; Beer DG
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4251-6. PubMed ID: 22375031
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Kim HS; Lee SE; Bae YS; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Shin SK; Lee SK; Lee YC; Kim HR; Shim YM; Jewell SS; Kim H; Choi YL; Cho BC
Oncotarget; 2016 May; 7(21):30691-701. PubMed ID: 27095573
[TBL] [Abstract][Full Text] [Related]
4. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma.
Yoon HH; Shi Q; Sukov WR; Lewis MA; Sattler CA; Wiktor AE; Wu TT; Diasio RB; Jenkins RB; Sinicrope FA
J Clin Oncol; 2012 Nov; 30(32):3932-8. PubMed ID: 22987085
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
[TBL] [Abstract][Full Text] [Related]
6. Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival.
Loeser H; Scholz M; Fuchs H; Essakly A; Damanakis AI; Zander T; Büttner R; Schröder W; Bruns C; Quaas A; Gebauer F
Sci Rep; 2020 Oct; 10(1):18411. PubMed ID: 33110104
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma.
Yoon HH; Sukov WR; Shi Q; Sattler CA; Wiktor AE; Diasio RB; Wu TT; Jenkins RB; Sinicrope FA
Cancer; 2014 Feb; 120(3):415-24. PubMed ID: 24151090
[TBL] [Abstract][Full Text] [Related]
8. Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma.
Lockwood WW; Thu KL; Lin L; Pikor LA; Chari R; Lam WL; Beer DG
Clin Cancer Res; 2012 Apr; 18(7):1936-46. PubMed ID: 22328562
[TBL] [Abstract][Full Text] [Related]
9. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.
Yoon HH; Shi Q; Sukov WR; Wiktor AE; Khan M; Sattler CA; Grothey A; Wu TT; Diasio RB; Jenkins RB; Sinicrope FA
Clin Cancer Res; 2012 Jan; 18(2):546-54. PubMed ID: 22252257
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis.
Essakly A; Loeser H; Kraemer M; Alakus H; Chon SH; Zander T; Buettner R; Hillmer AM; Bruns CJ; Schroeder W; Gebauer F; Quaas A
Transl Oncol; 2020 Feb; 13(2):157-164. PubMed ID: 31865178
[TBL] [Abstract][Full Text] [Related]
11. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
12. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
13. Dickkopf-2 (DKK2) as Context Dependent Factor in Patients with Esophageal Adenocarcinoma.
Schiffmann LM; Loeser H; Jacob AS; Maus M; Fuchs H; Zhao Y; Tharun L; Essakly A; Iannos Damanakis A; Zander T; Büttner R; Schröder W; Bruns C; Quaas A; Gebauer F
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32075129
[TBL] [Abstract][Full Text] [Related]
14. Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas.
Rehkaemper J; Korenkov M; Quaas A; Rueschoff J; Pamuk A; Zander T; Hillmer AM; Buettner R; Hoelscher AH; Bruns CJ; Loeser H; Alakus H; Schoemig-Markiefka B
BMC Cancer; 2020 Jun; 20(1):587. PubMed ID: 32571252
[TBL] [Abstract][Full Text] [Related]
15. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
Lennerz JK; Kwak EL; Ackerman A; Michael M; Fox SB; Bergethon K; Lauwers GY; Christensen JG; Wilner KD; Haber DA; Salgia R; Bang YJ; Clark JW; Solomon BJ; Iafrate AJ
J Clin Oncol; 2011 Dec; 29(36):4803-10. PubMed ID: 22042947
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.
Aichler M; Motschmann M; Jütting U; Luber B; Becker K; Ott K; Lordick F; Langer R; Feith M; Siewert JR; Walch A
Oncotarget; 2014 Aug; 5(16):6620-32. PubMed ID: 25216514
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of PIK3CA amplification in curatively resected liposarcoma.
Kim JH; Lee JS; Kim EJ; Park KH; Kim KH; Yi SY; Kim HS; Cho YJ; Shin KH; Ahn JB; Hu H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Noh SH; Rha SY; Kim HS
Oncotarget; 2016 Apr; 7(17):24549-58. PubMed ID: 27016421
[TBL] [Abstract][Full Text] [Related]
19. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
[TBL] [Abstract][Full Text] [Related]
20. A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas.
Adams O; Janser FA; Dislich B; Berezowska S; Humbert M; Seiler CA; Kroell D; Slotta-Huspenina J; Feith M; Ott K; Tschan MP; Langer R
PLoS One; 2018; 13(6):e0197610. PubMed ID: 29897944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]